Concepedia

Publication | Closed Access

Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.

10

Citations

0

References

2014

Year

V. Ektare, Janice Lopez, Silas C Martin, Dipen Patel, Marcia F.T. Rupnow, Marc Botteman
PubMed

Abstract

Canagliflozin 300 mg may represent a cost-efficient T2DM treatment option versus sitagliptin 100 mg for patients on metformin plus sulfonylurea due to lower overall costs and better achievement of A1C and quality composite goals.